ALZM huge news: Allezoe Medical signs exclusive license for HPV diagnostic technology
Comtex News Network "Datamonitor"
Dec 28, 2011 (Datamonitor via COMTEX) -- Allezoe Medical Holdings, Inc. , a developer of medical device and solutions, has announced that the company has acquired the exclusive license to develop and market patent pending, advanced 'see and treat' diagnostic technology for Human papillomavirus, or HPV, a sexually transmitted infection, or STI.
An exclusive license has been signed by SureScreen Medical, Inc. , a subsidiary of Allezoe, and AVM Corp. , which recently acquired the technology and the pending patent application from its developer, Aequorea Vision Medical, Inc. Under the terms of the license, SureScreen will develop and market products using the technology in return for a fixed royalty to AVM, commencing on sales of products using the technology.
As a result of the license, Allezoe holds the exclusive worldwide rights to this 'see and treat' technology which will allow healthcare providers to identify cell damage from HPV instantaneously, the company said.
Allezoe CEO Michael Gelmon says, "This is not a virus we have the luxury of ignoring, when hundreds of millions of people around the world are affected and are further spreading the virus. Our new licensed technology offers the combination of accuracy plus efficiency. This is a large market that we are looking forward to penetrating, and we have a strategy in place so we can hit the ground running."
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.